Theravance Biopharma (TBPH) Misses Q1 EPS by 5c, Beats on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 8, 2025 4:05 PM EDTYUPELRI® (revefenacin) net sales of $58.3 million, recognized by Viatris, increased 6% versus Q1 20241 TRELEGY net sales of $854M, as reported by GSK, increased 14% versus Q1 20242CYPRESS study open label enrollment nearing completion with final patient expected to be enrolled by late summerQuarter-end cash balance of $131 million, with no debtReaffirming all financial guidance metrics
DUBLIN, May 8, 2025 /PRNewswire/ --... More
